Physician profile
Gayle M Simmons
NPI 1154482024
$3,145.56
in general payments reported to CMS, 2019-2025
33 companies · $660 in 2025
The $660 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $90.04 · 2021: $352 · 2022: $591 · 2023: $600 · 2024: $382 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $507.56 | 2022-2025 | |
| Exeltis, USA INC. | $281.93 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $261.73 | 2019-2025 | Fluent Fluid Management System, Acessa Provu System, Aptima |
| Amgen INC. | $219.90 | 2019-2025 | Evenity, Prolia |
| Avion Pharmaceuticals | $180.72 | 2019-2022 | |
| Therapeuticsmd, INC. | $145.48 | 2021-2022 | |
| Abbvie INC. | $141.00 | 2019-2024 | |
| Myovant Sciences INC. | $127.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $103.94 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $103.41 | 2019-2023 | |
| Coopersurgical, INC. | $97.79 | 2019-2022 | |
| Glaxosmithkline, LLC. | $89.41 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Astellas Pharma US INC | $88.64 | 2022-2024 | Veozah, Myrbetriq |
| Duchesnay USA Incorporated | $83.76 | 2019 | |
| Lilly USA, LLC | $73.31 | 2022-2025 | Mounjaro, Zepbound, Emgality |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $73.09 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $68.07 | 2019-2023 | |
| Novo Nordisk INC | $56.33 | 2024 | Ozempic, Rybelsus |
| Agile Therapeutics, INC. | $51.69 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $51.48 | 2019 | |
| Organon LLC | $48.78 | 2022-2025 | Nexplanon, Nuvaring |
| Ascend Therapeutics US, LLC | $41.72 | 2021-2023 | |
| Allergan, INC. | $40.79 | 2019 | |
| Ethicon US, LLC | $35.87 | 2024 | Ethicon, Megadyne |
| Mylan Pharmaceuticals INC. | $30.86 | 2020-2021 | |
| Evofem Biosciences, INC. | $26.48 | 2022 | |
| Daiichi Sankyo INC. | $20.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.64 | 2024 | |
| Minerva Surgical, INC | $17.43 | 2019 | |
| Sanara Medtech INC. | $16.09 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.26 | 2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.20 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gayle Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.